Natera Inc
Research Natera Inc (NTRA) on Bullrun: market cap USD 48.36B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerNTRA
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryDiagnostics & Research
- CurrencyUSD
- Market capUSD 48.36B
- Financial periodQ2 2026
- RevenueUSD 752.75M
- Net income-USD 66.97M
- Free cash flow-USD 8.64M
- Gross margin64.5%
Valuation Snapshot
latest market cap is USD 48.36B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 2.31B | -USD 208.16M | USD 109.11M | 64.7% | -1.52 | USD 1.08B | USD 80.32M | USD 1.71B |
| FY2024 | USD 1.70B | -USD 190.43M | USD 69.24M | 60.3% | -1.53 | USD 945.59M | USD 80.36M | USD 1.20B |
| FY2023 | USD 1.08B | -USD 434.80M | -USD 286.15M | n/a | -3.78 | USD 642.10M | USD 363.35M | USD 765.33M |
| FY2022 | USD 820.22M | -USD 547.80M | -USD 479.20M | n/a | -5.57 | USD 466.01M | USD 362.00M | USD 705.74M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 48.36B | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 32.00B | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 21.00B | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 7.53B | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 4.45B | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 8.89B | n/a | n/a | n/a |
About Natera Inc
Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in patients previously diagnosed with cancer; Latitude, a blood-based MRD test for colorectal cancer; Altera, a tissue based comprehensive genomic profiling test; and Empower, a hereditary cancer screening test.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Natera Inc's market cap?
Natera Inc's market capitalization is USD 48.36B.
What does Natera Inc do?
Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in patients previously diagnosed with cancer; Latitude, a blood-based MRD test for colorectal cancer; Altera, a tissue based comprehensive genomic profiling test; and Empower, a hereditary cancer screening test.